abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’
Company profile
Ticker
ABCL
Exchange
Website
CEO
Carl L.G. Hansen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AbCellera Australia Pty Ltd. • AbCellera Biologics UK Ltd. • AbCellera Boston, Inc. • AbCellera Properties Inc. • AbCellera Properties Columbia Inc. • AbCellera Properties Evans Inc. • AbCellera US, Inc. • Biologiques AbCellera Québec Inc. • Lineage Biosciences Inc. • Trianni Inc. ...
ABCL stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
23 Feb 24
S-8
Registration of securities for employees
20 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
AbCellera Reports Full Year 2023 Business Results
20 Feb 24
8-K
Other Events
28 Nov 23
8-K
Results of Operations and Financial Condition
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Other Events
12 Oct 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
AbCellera Reports Q2 2023 Business Results
3 Aug 23
Transcripts
ABCL
Earnings call transcript
2023 Q3
2 Nov 23
ABCL
Earnings call transcript
2023 Q2
3 Aug 23
ABCL
Earnings call transcript
2023 Q1
4 May 23
ABCL
Earnings call transcript
2022 Q4
21 Feb 23
ABCL
Earnings call transcript
2022 Q3
8 Nov 22
ABCL
Earnings call transcript
2022 Q2
10 Aug 22
ABCL
Earnings call transcript
2022 Q1
11 May 22
ABCL
Earnings call transcript
2021 Q4
25 Feb 22
ABCL
Earnings call transcript
2021 Q3
10 Nov 21
ABCL
Earnings call transcript
2021 Q2
13 Aug 21
Latest ownership filings
4
Carl L. G. Hansen
27 Feb 24
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Hansen Carl L. G.
13 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
4
Veronique Lecault
16 Jan 24
4
Tryn Stimart
16 Jan 24
4
Andrew Booth
16 Jan 24
4
Carl L. G. Hansen
16 Jan 24
4
Change in insider ownership
19 Dec 23
4
Carl L. G. Hansen
27 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 197.42 mm | 197.42 mm | 197.42 mm | 197.42 mm | 197.42 mm | 197.42 mm |
Cash burn (monthly) | 2.44 mm | 16.63 mm | 18.30 mm | 17.41 mm | 35.33 k | (no burn) |
Cash used (since last report) | 16.34 mm | 111.28 mm | 122.44 mm | 116.51 mm | 236.45 k | n/a |
Cash remaining | 181.08 mm | 86.14 mm | 74.98 mm | 80.91 mm | 197.19 mm | n/a |
Runway (months of cash) | 74.2 | 5.2 | 4.1 | 4.6 | 5580.7 | n/a |
Institutional ownership, Q3 2023
65.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 138 |
Opened positions | 20 |
Closed positions | 49 |
Increased positions | 36 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 531.65 bn |
Total shares | 192.36 mm |
Total puts | 293.80 k |
Total calls | 789.00 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Carl L. G. Hansen | 55.86 mm | $0.00 |
Baillie Gifford & Co | 26.20 mm | $120.54 bn |
Baker Bros. Advisors | 20.76 mm | $95.51 bn |
Voya Investment Management | 10.62 mm | $48.87 bn |
Thiel Peter | 10.18 mm | $0.00 |
Capital World Investors | 8.42 mm | $38.73 bn |
DCVC Bio | 7.31 mm | $0.00 |
Credit Suisse | 4.57 mm | $21.04 bn |
Orbimed Advisors | 4.18 mm | $19.23 bn |
ArrowMark Colorado | 4.11 mm | $18.88 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 24 | Carl L. G. Hansen | Common Shares | Option exercise | Acquire M | No | No | 2.7 | 56,125 | 151.54 k | 729,625 |
26 Feb 24 | Carl L. G. Hansen | Share option Common Shares | Option exercise | Dispose M | No | No | 2.7 | 56,125 | 151.54 k | 8,428,598 |
14 Jan 24 | Carl L. G. Hansen | Share option Common Shares | Grant | Acquire A | No | No | 5.39 | 2,095,532 | 11.29 mm | 8,484,723 |
14 Jan 24 | Andrew Booth | Share option Common Shares | Grant | Acquire A | No | No | 5.39 | 770,416 | 4.15 mm | 6,590,897 |
14 Jan 24 | Tryn Stimart | Share option Common Shares | Grant | Acquire A | No | No | 5.39 | 616,333 | 3.32 mm | 3,274,714 |
14 Jan 24 | Veronique Lecault | Share option Common Shares | Grant | Acquire A | No | No | 5.39 | 770,416 | 4.15 mm | 3,913,105 |
News
AbCellera Presents Data On T-Cell Engagers Against Four Tumor Targets At AACR 2024
8 Apr 24
AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
11 Mar 24
Benchmark Upgrades AbCellera Biologics to Buy
22 Feb 24
Recap: AbCellera Biologics Q4 Earnings
20 Feb 24
AbCellera Biologics Q4 2023 GAAP EPS $(0.17) Misses $(0.13) Estimate, Sales $9.18M Beat $8.88M Estimate
20 Feb 24
Press releases
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
8 Apr 24
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
3 Apr 24
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
11 Mar 24
AbCellera Announces Resignation of Board Member
23 Feb 24
AbCellera to Present at Upcoming Investor Conferences in March
22 Feb 24